RT Journal Article
SR Electronic
T1 A Standardized Extract of Cultured <em>Lentinula edodes mycelia</em> Up-regulates COX-2 in Inflammation-related Malignant Progressive Fibrosarcoma Cell Clone QRsP-11
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1239
OP 1244
DO 10.21873/anticanres.16270
VO 43
IS 3
A1 KITAGAWA, TAKAO
A1 ISLAM, SHAJEDUL
A1 BARON, BYRON
A1 TOKUDA, KAZUHIRO
A1 PAUDEL, DURGA
A1 OHTA, TOHRU
A1 NAKAGAWA, KOJI
A1 KOBAYASHI, MASANOBU
A1 OKADA, FUTOSHI
A1 KURAMITSU, YASUHIRO
YR 2023
UL http://ar.iiarjournals.org/content/43/3/1239.abstract
AB Background/Aim: Cyclooxygenase is an enzyme that transforms arachidonic acid to prostaglandins. Cyclooxygenase-2 (COX-2) is an isoform of cyclooxygenase. There exist many reports on the expression levels of COX-2 in cancer tissues, and prognosis of cancer patients has been reported to be related to COX-2 up-regulation. In the present study we assessed the suppressive effect of AHCC® on the expression of COX-2 in QRsP-11cells. Materials and Methods: QR-32 is a clone which was derived from murine fibrosarcoma BMT-11 cells by treatment with quercetin. These clone cells regress spontaneously after injection into C57BL/6 mice. QRsP-11 is a clone derived from QR-32, showing very aggressive tumorigenicity. AHCC® is a standardized extract of cultured Lentinula edodes mycelia and has been reported to exert suppressive effects on various tumor-associated proteins including HSP27. The protein levels of COX-2 in QR-32 and QRsP-11 cells were compared by using western blotting. Furthermore, the expression levels of COX-2 were assessed in QRsP-11 cells after AHCC®-treatment. Results: Western blot analysis showed a significant up-regulation of COX-2 in QRsP-11 cells compared to QR-32 cells. In vitro AHCC®-treatment increased COX-2 expression levels in QRsP-11 cells contrary to expectations. Conclusion: When using AHCC® in cancer treatment, it might be important to decrease COX-2 expression by means of non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin. Further studies are required to clarify the mechanism of up-regulation of COX-2 through AHCC®-treatment.